… quarter of 2015 had a negative impact of roughly $750 million. On the operating front, the company’s Innovative Health segment, which sells newer, patent-protected drugs, contributed sales of $7.7 billion (+1%), driven by continued growth of …
… quarter of 2015 had a negative impact of roughly $750 million. On the operating front, the company’s Innovative Health segment, which sells newer, patent-protected drugs, contributed sales of $7.7 billion (+1%), driven by continued growth of …